Alpha interferon dose-dependent suppression of secondary clones in a patient with Philadelphia-positive chronic myelogenous leukemia

David Claxton, H. Kantarjian, R. Kurzrock, J. M. Trujilo, J. U. Gutterman, M. Talpaz

Research output: Contribution to journalArticle

5 Scopus citations

Abstract

A patient whose chronic myelogenous leukemia (CML) was treated with interferon alpha (IFN-α) is described. The disease showed karyotypic evolution during the chronic phase and the later myeloid acceleration. Both of these secondary clonal phenomena responded to IFN-α dose escalation. The case illustrates the dose dependence of CML responses to IFN-α. The phenomenon of clonal evolution is discussed in the context of this patient's disease.

Original languageEnglish (US)
Pages (from-to)149-151
Number of pages3
JournalActa Haematologica
Volume83
Issue number3
DOIs
StatePublished - Jan 1 1990

All Science Journal Classification (ASJC) codes

  • Hematology

Fingerprint Dive into the research topics of 'Alpha interferon dose-dependent suppression of secondary clones in a patient with Philadelphia-positive chronic myelogenous leukemia'. Together they form a unique fingerprint.

  • Cite this